BioSenic receives EUR 1 million from Pregene in accordance with terminated license agreement and expect new negotiations on common revisited grounds
Following the regaining of ALLOB global rights, BioSenic has received a final payment from Pregene linked to a previously achieved development milestone which has a significant impact on the financial fundamentals of BioSenic
BioSenic continues to conduct preliminary discussions with Pregene, Link Health and other potential partners to move forward with the development and commercialization of ALLOB in other geographies, including the US
Mont-Saint-Guibert, Belgium, February 21, 2023, 7am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune / inflammatory diseases and cell repair, today announces it has received EUR 1 million (minus 6% taxes) from Pregene.
On 5 October 2020, BioSenic, Pregene and Link Health Pharma Co., Ltd (“Link Health”) signed an exclusive license agreement for the manufacturing, clinical development and commercialization of ALLOB in China (including Hong Kong and Macau), Taiwan, Singapore, South Korea, and Thailand).
Het had iets meer mogen zijn maar op een rode dag zullen we niet klagen zeker.
0,2075 +0,0189 (10,02%)
We zouden eerst door die 0.25 moeten kunnen.
0,21 46.000 2
0,216 8.000 1
0,22 8.650 3
0,23 2.700 2
0,2495 10.000 1
0,25 323.552 8
0,255 10.624 2
0,257 30.000 1
0,267 3.750 1
0,27 15.000 1
Dan mogen ze nog wat positieve persberichten uitsturen en dan hun kapitaalverhoging aanbieden aan 0.45 als de koers dan een stuk hoger staat.